Chemoprevention in ulcerative colitis: Narrowing the gap between clinical practice and research

E. T. Hawk; J. L. Viner

doi:10.7326/0003-4819-134-2-200101160-00017

Chemoprevention in ulcerative colitis: Narrowing the gap between clinical practice and research

E. T. Hawk, J. L. Viner

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

At present, it would be premature to offer ursodiol as a chemopreventive agent outside the context of a clinical trial. However, if the inverse association between ursodiol use and dysplasia prevalence described by Tung and colleagues in this issue is causal and true, it is a very exciting observation.

Original language	English (US)
Pages (from-to)	158-160
Number of pages	3
Journal	Annals of internal medicine
Volume	134
Issue number	2
DOIs	https://doi.org/10.7326/0003-4819-134-2-200101160-00017
State	Published - Jan 16 2001
Externally published	Yes

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.7326/0003-4819-134-2-200101160-00017

Cite this

@article{495bb3f5de31421fbac3404089434c43,

title = "Chemoprevention in ulcerative colitis: Narrowing the gap between clinical practice and research",

abstract = "At present, it would be premature to offer ursodiol as a chemopreventive agent outside the context of a clinical trial. However, if the inverse association between ursodiol use and dysplasia prevalence described by Tung and colleagues in this issue is causal and true, it is a very exciting observation.",

author = "Hawk, {E. T.} and Viner, {J. L.}",

year = "2001",

month = jan,

day = "16",

doi = "10.7326/0003-4819-134-2-200101160-00017",

language = "English (US)",

volume = "134",

pages = "158--160",

journal = "Annals of internal medicine",

issn = "0003-4819",

publisher = "American College of Physicians",

number = "2",

}

TY - JOUR

T1 - Chemoprevention in ulcerative colitis

T2 - Narrowing the gap between clinical practice and research

AU - Hawk, E. T.

AU - Viner, J. L.

PY - 2001/1/16

Y1 - 2001/1/16

N2 - At present, it would be premature to offer ursodiol as a chemopreventive agent outside the context of a clinical trial. However, if the inverse association between ursodiol use and dysplasia prevalence described by Tung and colleagues in this issue is causal and true, it is a very exciting observation.

AB - At present, it would be premature to offer ursodiol as a chemopreventive agent outside the context of a clinical trial. However, if the inverse association between ursodiol use and dysplasia prevalence described by Tung and colleagues in this issue is causal and true, it is a very exciting observation.

UR - http://www.scopus.com/inward/record.url?scp=0035895303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035895303&partnerID=8YFLogxK

U2 - 10.7326/0003-4819-134-2-200101160-00017

DO - 10.7326/0003-4819-134-2-200101160-00017

M3 - Review article

C2 - 11177320

AN - SCOPUS:0035895303

SN - 0003-4819

VL - 134

SP - 158

EP - 160

JO - Annals of internal medicine

JF - Annals of internal medicine

IS - 2

ER -

Chemoprevention in ulcerative colitis: Narrowing the gap between clinical practice and research

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this